FLIKER - An open label phase II study evaluating the effectiveness of first line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients selected by positive FISH EGFR test

LA-REMA - Retrospective analysis of molecular factors predictive for clinical efficacy of lapatinib in HER2-positive advanced breast cancer patients.

PathIES - Intergroup Exemestane Study Pathology Sub-Study

ACELUNG - Phase III trial evaluating the role of adjuvant celecoxib in completely resected, high-risk (pN1-2) non-small-cell lung cancer (NSCLC) patients.

OLYMPIA, D081CC00006 - A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

APHINITY - A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer, BO25126

BIG 1-98 - A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors

CLOVIS CO-1686-006 - A prospective study to evaluate the concordance of tumor-associated mutations detected in matched tumor and blood samples in patients with NSCLC with known epidermal growth factor receptor mutational status

INSIGHT - Imlepmentation of Presonalized Medicine in NSCLC: EGFR testing, histopatological an clinical features